China's State Council issues Decree No. 834 on supply chain security
Updated
Updated · STAT · May 4
China's State Council issues Decree No. 834 on supply chain security
12 articles · Updated · STAT · May 4
The April 7 rules took effect immediately with no transition period and span 18 articles covering foreign companies whose decisions are judged to harm China's industrial chain security.
The decree gives Beijing broad powers to investigate and sanction firms, especially as biotechnology and pharmaceuticals become central to China's 15th five-year industrial plan.
It comes as China has expanded from under 8% of global clinical trials in 2010 to more than 5,000 annually in 2024, overtaking the US by 2020.
As China’s drug innovation soars, will its new security decrees create a 'biotech iron curtain'?
Will the US-China biotech rivalry accelerate drug discovery or create global shortages of critical medicines?
China’s Supply Chain Security Laws 2026: Impact, Risks, and Global Mineral Supply Disruptions
Overview
In 2026, China enacted State Council Order No. 834, immediately effective, imposing strict controls on supply chain security and data collection, especially in key sectors like lithium-ion batteries and rare earths. This created a compliance dilemma for multinational corporations caught between Chinese restrictions and Western ESG and forced labor laws. Building on this, Decree No. 835 introduced a Malicious Entity List to penalize foreign entities enforcing sanctions China deems improper. These measures, driven by China's dual circulation strategy prioritizing domestic resilience and technological self-reliance, have disrupted global critical mineral supply chains, prompting US and allies to pursue reshoring. Corporations now adopt cautious communication and discreet diversification to navigate this complex, high-risk environment.